Core Viewpoint - The company Shijiazhuang Four Medicines Group (02005) has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredients, including m-aminophenol dimethyl ether and dobutamine hydrochloride, for use in marketed formulations [1] Group 1: Product Approvals - The m-aminophenol dimethyl ether is primarily used for the preparation of m-aminophenol injection, which treats acute spasm pain caused by digestive system and biliary dysfunction, acute spasmodic urethral, bladder, and renal colic, as well as gynecological spasmodic pain [1] - The company has obtained the production registration certificate for m-aminophenol injection from the National Medical Products Administration, as stated in its announcement dated August 27, 2024 [1] Group 2: Therapeutic Applications - Dobutamine hydrochloride is mainly used for the preparation of dobutamine hydrochloride injection, which is indicated for heart failure caused by decreased myocardial contractility in organic heart disease, including low cardiac output syndrome following cardiac surgery [1]
石四药集团：间苯三酚三甲醚及盐酸多巴酚丁胺已获国家药监局批准登记成为在上市制剂使用的原料药